Methylene blue is one of the oldest synthetic medicines still in daily use, a deep blue dye first made in 1876 and still the hospital antidote for a blood emergency called methemoglobinemia. At low doses it also acts on the energy-producing machinery inside cells, which is the basis for a small but growing research interest in memory and metabolism, and for a wellness-supplement trend that sells it in dropper bottles for energy, focus, and longevity. That trend runs ahead of the human evidence: the strongest brain trial in its lineage, a phase 3 study of a stabilized derivative in Alzheimer disease, was negative, and the trend skips the interaction that makes methylene blue dangerous.
It is a potent MAO-A inhibitor, so combined with common antidepressants it can cause serotonin syndrome, a dangerous and sometimes fatal reaction. It also breaks down red blood cells in people with G6PD deficiency, and its safe dose window is narrow. This page is educational and gives no dose or source.
Findings & Outcomes
What It Is
Methylene blue is a synthetic dye, a vivid blue powder that dissolves in water, first synthesized in 1876 and used as the first fully synthetic pharmaceutical. It has served as a textile dye, a laboratory and surgical stain that makes tissue visible, an early antimalarial, and, most durably, a medicine. Its enduring medical role is as the standard antidote for methemoglobinemia, a condition in which the iron in hemoglobin is chemically altered so it can no longer carry oxygen.
One chemical property explains the rest. Methylene blue readily accepts and gives up electrons, which lets it act directly on the energy-producing machinery inside cells. That is the basis of its low-dose research story and of its narrow safe range. Three uses share the one name: an approved medicine at a defined dose and setting, a set of early research findings, and a wellness-supplement trend that has moved ahead of both.
Anatomy Of An Electron Cycler
1A redox-active molecule
Methylene blue is redox-active, meaning it swings easily between an oxidized blue form and a reduced colorless form by picking up and dropping electrons. That single chemical trait explains most of what the compound does, from staining tissue blue to acting on cell energy production. Its effects are broad and depend heavily on dose because it carries electrons through cell chemistry.
2Support for the energy chain at low doses
Inside the mitochondria, the energy-producing structures of the cell, electrons pass down a chain of proteins to make usable energy. At low concentrations methylene blue carries electrons within that chain and raises the activity of its final enzyme, which supports energy output. This is the mechanism behind the low-dose memory and metabolism research.
3A hormetic dose-response
The helpful effect follows an inverted-U curve, a hormetic dose-response: a low dose supports mitochondrial energy, while a higher dose reverses the same chemistry into a pro-oxidant, energy-impairing effect. This is why with methylene blue a higher dose is not a better one and can be worse, and why the safe range is narrow.
How It Works
Methylene blue moves electrons, and the direction of the effect depends on the dose. In its established medical use it donates electrons to an enzyme pathway that converts the oxygen-blocked form of hemoglobin back into the form that carries oxygen, which is why methemoglobinemia reverses within minutes to an hour of a low intravenous dose. In its research use the same electron-carrying ability feeds the mitochondrial electron transport chain and raises the activity of cytochrome c oxidase, the chain's final enzyme, which increases how much energy a cell can produce. This connects the animal memory studies, the human brain-imaging signal, and the idea that low-dose methylene blue supports cellular energy. For the machinery it acts on, see mitochondria and energy.
Everything turns on dose. The low-dose, energy-supporting effect and the high-dose, energy-impairing effect are the same chemistry running in opposite directions, which is what a hormetic dose-response means and why the effective range is narrow. A second mechanism governs the safety picture: methylene blue is a potent inhibitor of monoamine oxidase A, the enzyme that clears serotonin.
Because methylene blue is a potent MAO-A inhibitor, combining it with an SSRI, SNRI, or other serotonergic drug can cause serotonin syndrome, a dangerous and sometimes fatal reaction. The cautions cover it in full.
Where The Research Stands
The strongest evidence for methylene blue is its use as the standard antidote for methemoglobinemia, an FDA-approved, first-line treatment stocked in hospitals. Given at a low dose by vein, it restores the blood's ability to carry oxygen within minutes to an hour. The evidence is roughly 150 years of clinical use and documented case series rather than large randomized trials, which is common for a drug that predates the modern trial era, and that long record is itself a form of evidence: a compound given and observed in medicine since the 1870s has reached far more patients over far more time than any single trial could cover.
Methylene blue has other defined medical uses at controlled doses under supervision:
- A surgical and diagnostic dye that makes specific tissues visible during an operation.
- A reported treatment for ifosfamide-induced encephalopathy, the acute confusion the chemotherapy drug ifosfamide can cause.
- An investigational use in vasoplegic syndrome, a dangerous drop in blood-vessel tone during and after some surgeries.
The cognition and memory work is where the evidence is still emerging, and it sits well below the antidote use in strength. It rests on a mechanism, animal studies, and a single small human brain-imaging trial of one acute dose measuring a laboratory task. Read against everyday memory in healthy people, this is a signal to watch, not an established benefit.
The largest and most rigorous test of this drug family in the brain was negative. A stabilized derivative, LMTM, developed as a tau-aggregation inhibitor, was taken into a large phase 3 trial in Alzheimer disease and did not produce the hoped-for benefit. That result concerns the derivative, not methylene blue sold as a supplement, and it does not settle the separate question of low-dose use in healthy people, but it is the strongest test of the family in dementia to date, and it tempers the enthusiasm the earlier signals generated.
The low-dose wellness use, blue drops taken for energy, focus, and longevity, runs ahead of the human evidence for those specific claims, and it tends to leave out two things a medical setting would put first: the serious interaction with serotonergic drugs, and the narrow dose window that separates a helpful low dose from a harmful high one. Grade is a further practical concern. Pharmaceutical-grade methylene blue is purified to strict standards, while dye-grade or laboratory-grade material can carry metal and other contaminants and is not made for human consumption, so purity cannot be judged by the color. Methylene blue is an approved medicine with an early research signal attached, and the wellness market sells that combination as a settled energy supplement while the human evidence is thin and a serious interaction goes mostly unmentioned. This page is educational and gives no dose or source.
The findings below are graded at the strength of their own evidence.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Anemia And Iron
The standard antidote for methemoglobinemia, restoring oxygen within the hour
Given by vein at a low dose, methylene blue is the go-to hospital treatment for methemoglobinemia, a blood emergency where oxygen cannot be delivered. It flips the blood chemistry back so oxygen moves again, usually within the hour.
Methemoglobinemia is a state, usually triggered by certain drugs or chemicals, in which hemoglobin iron is oxidized from the ferrous to the ferric form and can no longer bind oxygen, so tissues starve despite a normal oxygen supply. Methylene blue is reduced by NADPH-dependent enzymes to leucomethylene blue, which then chemically reduces the ferric iron back to the oxygen-carrying ferrous state. Given intravenously at a low dose, it acts within minutes and is the accepted first-line treatment. The evidence base is long clinical experience and case series across decades of use rather than large randomized trials, and it is well established enough to be a labeled indication.
The study · 1
Clifton 2003, Methylene blue (clinical review) · Am J Ther 2003
Cognition
No slowing of Alzheimer decline in an 891-patient trial of the derivative LMTM
A big, well-run trial of a drug built from methylene blue to target the tau protein in Alzheimer disease did not beat the comparison group on its main measures. The high hopes for this route have largely not been borne out.
LMTM (leuco-methylthioninium, a reduced, more stable relative of methylene blue) was advanced as a tau-aggregation inhibitor for Alzheimer disease. In a large randomized, controlled, double-blind, parallel-arm phase 3 trial in mild-to-moderate Alzheimer disease, adding LMTM to standard therapy did not produce a benefit over control on the co-primary cognitive and functional endpoints. This is the most rigorous test of the methylene blue lineage in dementia to date, and its result tempers the enthusiasm generated by the earlier signals. It concerns the derivative, not methylene blue sold as a supplement.
The study · 1
Gauthier 2016, phase 3 tau-aggregation inhibitor trial in Alzheimer disease · Lancet 2016
A single dose raised memory retrieval 7% in a 26-person MRI trial
In one small controlled human study, a single low dose lit up more brain activity during a memory task and went along with slightly better recall. It is an early signal, not a settled result.
Rodriguez and colleagues ran a randomized, double-blind, placebo-controlled multimodal functional MRI study of a single low oral dose of methylene blue in healthy adults. The active dose produced larger blood-oxygen-level-dependent responses in brain regions supporting sustained attention and short-term memory, and a measurable increase in correct responses on a memory-retrieval task. The study is small, tests a single acute dose in healthy people, and measures a laboratory task rather than everyday memory, so it establishes a plausible short-term signal rather than a durable cognitive benefit.
The study · 1
Rodriguez 2016, functional MRI of methylene blue in the human brain · Radiology 2016
Cleared and prevented ifosfamide chemotherapy confusion across 12 reported cases
When the chemotherapy drug ifosfamide causes sudden confusion, methylene blue has been reported to help clear it and to prevent it coming back with later doses. This rests on case reports, not controlled trials.
Ifosfamide can cause an acute encephalopathy with confusion and reduced consciousness. Pelgrims and colleagues reported 12 cases and reviewed the literature, describing methylene blue given both to reverse established ifosfamide encephalopathy and to prevent it in patients who required continued ifosfamide treatment. The reported responses were favorable, but the evidence is uncontrolled case experience, in which spontaneous recovery cannot be excluded, so the practice is supported but not proven by trial.
The study · 1
Pelgrims 2000, methylene blue in ifosfamide-induced encephalopathy (12 cases and review) · Br J Cancer 2000
Low-dose methylene blue improved memory in rats, 66% versus 31% correct
In rats, a low dose helped them hold on to what they had learned and raised the activity of a key energy enzyme in memory areas of the brain. Animal work points the way but does not carry across to people on its own.
Callaway and colleagues gave rats low-dose methylene blue and found improved retention on a baited holeboard spatial-memory task with repeated post-training dosing, alongside a measurable increase in cytochrome c oxidase activity after a dose, the terminal enzyme of oxidative phosphorylation, in brain regions involved in memory. The finding is the animal basis for the idea that low-dose methylene blue supports mitochondrial energy metabolism and, through it, memory. It is a rodent study of an acute dose and does not establish an effect in humans.
The study · 1
Callaway 2004, methylene blue improves brain oxidative metabolism and memory retention in rats · Pharmacol Biochem Behav 2004
How it works
A potent MAO-A blocker, the basis for its serotonin-toxicity danger
Methylene blue strongly blocks an enzyme that clears serotonin from the body. That single fact is the reason it can combine dangerously with common antidepressants, explained in the cautions.
Ramsay and colleagues measured the inhibition of monoamine oxidase A by methylene blue and confirmed it is a potent MAO-A inhibitor, matching the prediction made from clinical serotonin-toxicity reports. Monoamine oxidase A is a primary route for degrading serotonin, so blocking it while serotonin availability is already raised by a serotonergic drug allows serotonin to accumulate. This is a mechanism claim: it does not by itself quantify a clinical risk, but it is the biochemical basis for the serious drug interaction that dominates the safety picture.
The study · 1
Ramsay 2007, methylene blue inhibition of monoamine oxidase A · Br J Pharmacol 2007
An electron cycler that raises cytochrome c oxidase activity at low doses
Methylene blue can shuttle electrons inside the mitochondria, the cell's energy-producing machinery, giving them a small assist at low doses. Push the dose up and the same chemistry turns unhelpful, which is why more is not better here.
Rojas and colleagues reviewed the neurometabolic actions of methylene blue. As a redox-cycling agent it can be reduced and re-oxidized within the electron transport chain, acting as an alternative electron carrier that bypasses parts of the chain and increases cytochrome c oxidase activity, which raises mitochondrial oxygen consumption and energy output at low doses. The effect follows an inverted-U (hormetic) dose-response: low concentrations enhance metabolism while higher concentrations promote oxidation and impair it. This mechanism is the throughline connecting the animal memory findings and the human imaging signal, and it is drawn mainly from cell and animal work.
The study · 1
Rojas 2012, neurometabolic mechanisms of methylene blue · Prog Neurobiol 2012
Mood & stress
Eased residual depression and anxiety in a small bipolar trial, 195 mg versus 15 mg
In one small crossover trial in people with bipolar disorder, methylene blue eased leftover depression and anxiety a little. It is a single small study, and mood was an old and mostly preclinical interest before it.
Alda and colleagues ran a randomized, double-blind crossover trial of methylene blue in 37 patients with bipolar disorder maintained on lamotrigine, comparing an active 195 mg dose against a 15 mg dose treated as a near-placebo. The active dose was associated with lower residual depressive and anxiety symptom scores, without a significant effect on mania. Interest in methylene blue for mood dates back to older and largely preclinical work; this crossover trial is the more modern human signal. It is small, tests an add-on in an already-treated population, and needs replication.
The study · 1
Alda 2017, methylene blue for residual symptoms of bipolar disorder (randomized crossover) · Br J Psychiatry 2017
Go Deeper
- Mitochondria and energy: the cell energy machinery methylene blue acts on, why building mitochondria through training is solid, and why most supplement shortcuts to the same end are not.
- IV vitamin drips and NAD+ therapy: the neighboring wellness category, where raising a marker gets sold as improving an outcome, and the same distinction applies.
- Biological aging: the longevity biology the low-dose energy trend is marketed against, and how to weigh a mechanism that points one way when the outcome may not follow.
- BDNF and the exercising brain: the brain-and-cognition biology behind memory and mood, and the practices with the firmest evidence for supporting it.
The Chinese Medicine View
Methylene blue is a modern synthetic compound, invented in a laboratory in 1876, with no place in the classical Chinese pharmacopoeia. No historical text assigns it a channel, a temperature, or a flavor, and there is no traditional preparation that resembles it. What follows sets it beside the tradition as a lens, not as evidence, and it borrows no classical claim, because none exists. Nothing here should be read as a suggestion that methylene blue is traditional or that Chinese medicine endorses it.
The one overlap between the frameworks is where each locates vitality. A modern account makes the mitochondrion the site where fuel and oxygen are burned to release usable energy, and methylene blue is of interest because it acts on that machinery at low doses. The tradition, with no way to see a cell, placed a source of warmth and activation at the root of the body, often described as the Ming Men fire tied to Kidney Yang, and made it the thing that powers every transformation and digestion.
Both frameworks put a source of cellular or bodily energy at the center of vitality. The overlap goes no further: Qi is not electron flow, Yang is not a mitochondrion, and a practitioner working from this framework would be reading the pulse, the tongue, and the person in front of them, not dosing a synthetic dye. The tradition would also hold that forcing a system with a potent substance is a different act from cultivating vitality steadily, a caution that lands cleanly on a compound with a narrow safe range and a serious interaction.
Cautions For This Practice
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Serotonin syndrome, a life-threatening reaction, when combined with antidepressants
Gillman synthesized the pharmacology and case evidence showing that methylene blue, through potent monoamine oxidase A inhibition, is the exemplar for drug interactions that precipitate serotonin toxicity. When it is given to a person taking an SSRI, SNRI, certain other antidepressants, or another serotonergic agent, serotonin can rise to toxic levels, producing agitation, hyperthermia, muscle rigidity, clonus and autonomic instability that can progress to a medical emergency. Documented cases include severe and fatal outcomes, and regulators have warned specifically about methylene blue given during serotonergic drug treatment. This interaction is the reason methylene blue is a prescription-context drug and why the wellness trend around it is concerning.Gillman 2011, CNS toxicity of methylene blue and serotonin toxicity interactions
Red-cell breakdown in G6PD deficiency, and methemoglobinemia at high doses
Methylene blue relies on a G6PD-dependent supply of NADPH to be reduced to its active antidote form. In G6PD deficiency that supply is low, so the drug is both less effective and can itself provoke oxidative hemolysis, which is the basis for avoiding it in that population. Separately, the dose-response is biphasic: at low doses it reduces methemoglobin, while at high doses it becomes a pro-oxidant and can cause methemoglobinemia, the condition it is used to treat. Both points come from the clinical pharmacology summarized in the standard review and are why dosing and screening belong with a clinician.Clifton 2003, Methylene blue (clinical review)
Serotonin syndrome with antidepressants and other serotonergic drugs
Methylene blue is a potent inhibitor of monoamine oxidase A, the enzyme that clears serotonin, so combining it with SSRIs, SNRIs, certain other antidepressants, or other serotonin-raising medicines can precipitate serotonin syndrome. That is a potentially life-threatening reaction with agitation, high fever, muscle rigidity, and unstable heart rate and blood pressure. Severe and fatal cases are on record, and drug regulators have warned about it specifically. Many people who might use a methylene blue supplement already take these medications, which is what makes the interaction so serious. If you take an antidepressant or any serotonergic drug, treat this as a serious danger to raise with your clinician.
G6PD deficiency and the risk of red-cell breakdown
People with the inherited enzyme condition glucose-6-phosphate dehydrogenase (G6PD) deficiency can suffer acute breakdown of red blood cells after methylene blue, and the drug is both less effective and potentially harmful in that setting. G6PD deficiency is common in some populations and is often undiagnosed, so a person may not know they carry it. This is a core reason methylene blue belongs in a supervised medical setting where a clinician can screen for it first.
A narrow dose window and paradoxical methemoglobinemia
Methylene blue has a hormetic dose-response: a low dose supports the effect, while a high dose reverses the same chemistry and becomes a pro-oxidant. At high doses it can itself cause methemoglobinemia, the very condition it treats at low doses. With this compound a higher dose is not a safer one, and the helpful range is narrow.
Pregnancy and breastfeeding
Methylene blue is generally avoided in pregnancy outside a clear medical emergency, as higher-dose exposure has been linked to harm to the developing baby, and its safety in breastfeeding is not established. Anyone who is pregnant, planning pregnancy, or breastfeeding should treat it as off-limits without direct medical guidance.
Pharmaceutical grade versus dye grade
Pharmaceutical-grade methylene blue is purified to strict standards for human use, while dye-grade or laboratory-grade material can contain metal and other contaminants and is not manufactured for consumption. The blue color is identical, so grade cannot be judged by eye, and the difference matters for safety.
A prescription-context medicine, and other effects
Methylene blue is a medicine with documented interactions, used at defined doses and in defined settings. It turns urine and sometimes the whites of the eyes blue or green, which is harmless but startling, and it can interfere with pulse oximeter readings. Given its interaction profile and narrow dose range, decisions about it belong with a clinician who knows your medications and health history, not a supplement label.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
What is methylene blue used for medically?
Its established use is as the standard antidote for methemoglobinemia, a state in which the blood cannot carry oxygen. Given at a low dose by vein, it restores oxygen transport within minutes to an hour, and this use is FDA-approved, first-line, and stocked in hospitals. It also serves as a surgical and diagnostic dye that makes tissue visible during operations, has a reported role in reversing the confusion the chemotherapy drug ifosfamide can cause, and has been investigated in a dangerous drop in blood-vessel tone during surgery. These are defined medical uses at controlled doses under supervision.
Does methylene blue actually improve memory or focus?
The evidence is emerging, not established. A small, well-run, placebo-controlled human brain-imaging study in 26 healthy adults found that a single low dose raised brain activity during a memory task and went along with a 7% rise in correct answers, and rat studies point the same way through a clear energy-metabolism mechanism, with treated animals making 66% correct choices against 31% for controls. The human data still rest on one small acute-dose trial measuring a laboratory task, and the largest brain trial in the family, a phase 3 study of a methylene blue derivative in 891 patients with Alzheimer disease, did not show the hoped-for benefit. This is a signal, not a demonstrated everyday cognitive benefit.
Why is methylene blue dangerous with antidepressants?
Because methylene blue is a potent inhibitor of monoamine oxidase A, the enzyme that clears serotonin from the body. If you take an SSRI, SNRI, or another serotonergic drug, blocking that enzyme lets serotonin rise to toxic levels, which can trigger serotonin syndrome, a potentially life-threatening reaction with agitation, high fever, muscle rigidity, and unstable vital signs. Severe and fatal cases are documented, and regulators have warned about it. This is the main reason decisions about methylene blue belong with a clinician.
Is low-dose methylene blue safe to take as a supplement?
It carries risks that set it apart from an ordinary supplement. The interaction with antidepressants and other serotonergic drugs is the largest, red-cell breakdown in people with G6PD deficiency is another, and the dose window is narrow, with high doses causing the blood problem the drug treats at low doses. Grade matters too, because dye-grade material is not made for human use and looks identical to the pharmaceutical form. This page is educational and gives no dose or source; the evidence points to a medicine with a serious risk profile.
Why does methylene blue turn urine blue or green?
Because it is a strong dye, and the body clears part of it through the kidneys. The color passing into urine, and sometimes a bluish tint to the whites of the eyes, is a harmless and expected effect of the dye itself. It can also briefly throw off the reading on a pulse oximeter, the finger clip that measures blood oxygen. These visible effects are cosmetic; the effects that matter for safety are the drug interactions and dose range set out in the cautions.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
How this connects
- How it works
-
- Hormesis · Methylene blue's benefit follows a hormetic inverted-U: the low dose that supports mitochondrial energy becomes a pro-oxidant at a high one, the same chemistry running in reverse.
All 10 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.